Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well cisplatin with or without WEE1 inhibitor
MK-1775 works in treating patients with head and neck cancer that has come back or has spread
to other parts of the body. Drugs used in chemotherapy, such as cisplatin, may prevent tumor
cells from multiplying by damaging their deoxyribonucleic acid (DNA), which in turn stops the
tumor from growing. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. It is not yet known whether cisplatin is more
effective with or without WEE1 inhibitor MK-1775 in treating patients with head and neck
cancer.